The U.S. Food and Drug Administration (FDA) has approved Vyjuvek (beremagene geperpavec), Krystal Biotech’s gene therapy gel, for treating…
Articles by Marta Figueiredo, PhD
Krystal Biotech’s gene therapy gel Vyjuvek (beremagene geperpavec) for dystrophic epidermolysis bullosa (DEB) has been granted priority review…
The European Commission has approved Amryt Pharma’s Filsuvez (Oleogel-S10) for the treatment of skin wounds in adults and children, ages…
Vyjuvek, a gene therapy gel (previously called B-VEC) by Krystal Biotech, safely and effectively improved wound healing in children and…
The U.S. Food and Drug Administration (FDA) has rejected an application seeking approval of Filsuvez (Oleogel-S10) for treating skin…
Transplanting a patient’s own genetically corrected skin grafts safely and effectively treated skin loss and ulcers affecting 80% of the…
The European Medicines Agency (EMA) is seeking the opinion of independent epidermolysis bullosa (EB) experts and patients before issuing its…
With the new school year launching, the Dystrophic Epidermolysis Bullosa Research Association of America — better known as debra…
Dominant dystrophic epidermolysis bullosa (DEB) may lead to congenital deformities such as disproportionately short great (big) toes, according to…
Eloxx Pharmaceuticals announced ZKN-013 as its lead oral treatment candidate for recessive dystrophic epidermolysis bullosa (RDEB) and junctional…
Excessive thickening of the skin on the soles of the feet (plantar keratoderma) is a common and serious complication of all…
Using exon skipping therapies may be an easy, affordable, and effective approach for people with epidermolysis bullosa (EB) with amenable mutations,…